<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="47418" whole_study_id="27599" phs="001570" v="3" createDate="2022-06-02T09:55:16-05:00" modDate="2022-06-02T09:55:18-05:00" maxParentChildStudyModDate="2022-06-02T09:55:18-05:00" handle="CALGB_40601" num_participants="265"><StudyInfo accession="phs001570.v3" parentAccession="phs001570.v3"><BioProject id="PRJNA448796" entrez_id="448796" type="bp_admin_access"/><BioProject id="PRJNA448797" entrez_id="448797" type="bp_data_submission"/><StudyNameEntrez>CALGB 40601: Randomized Phase 3 Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Breast Cancer </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="whole_targ_exome"/><StudyType22 name="rnaseq_whole_targ_transcriptome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="germline"/><StudyType22 name="dna"/><StudyType22 name="rna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>germline</StudyType><StudyType>dna</StudyType><StudyType>rna</StudyType><StudyType>whole_exome</StudyType><StudyType>whole_transcriptome</StudyType><StudyType>rna_seq_derived_expression</StudyType></StudyTypes><Funding>U10CA031946</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="CAREYL" aid="2" auth="eRA" login="CAREYL" fname="LISA" mname="" lname="CAREY" email="Lisa_Carey@med.unc.edu"><Role>PI</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILL</Organization></Person><Person nedid="0011263528" aid="1" auth="cit" login="mooneym" fname="Margaret" mname="Marian" lname="Mooney" email="mm723k@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="PASPEARS" aid="2" auth="eRA" login="PASPEARS" fname="Patricia" mname="" lname="Spears" email="paspears@med.unc.edu"><Role>PI_ASSIST</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILLDUKE UNIVERSITY</Organization></Person><Person nedid="0012988688" aid="1" auth="cit" login="popovan" fname="Natalia" mname="V" lname="Popova" email="popovan@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>Funding: The Alliance for Clinical Trials in Oncology NIH-NCI grants U10CA180821 and CALGB U10CA031946; Alliance Statistical Center Grant U10CA180882 and CALGB U10CA33601; Alliance NCTN Biorepository and Biospecimen Resource 5U24CA196171.   CALGB 40601 study PI Lisa M. Carey. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. U10CA031946; U10CA180821</acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=28797&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx" md5="36771c6ad50340f0d6ced43a3dd3e2d0" size="57789" modDate="2018-04-03T07:16:35-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=36239&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx.pdf" md5="9ab18a3c50e6a616490b932445e92d12" size="444372" modDate="2019-09-12T09:18:46-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="2831" CGType="cg_class_HMB" title="Health/Medical/Biomedical (COL)" name="HMB-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to NCICTEPDAR@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPDAR@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="2" name="complete" title="Awaiting GPA's Approval"/></Study><Study uid="36148" whole_study_id="27599" phs="001570" v="2" p="1" createDate="2019-09-11T10:28:50-05:00" completedByGPADate="2019-09-30T06:54:22-05:00" modDate="2022-06-02T09:55:18-05:00" maxParentChildStudyModDate="2022-06-02T09:55:18-05:00" handle="CALGB_40601" num_participants="265"><StudyInfo accession="phs001570.v2.p1" parentAccession="phs001570.v2.p1"><BioProject id="PRJNA448796" entrez_id="448796" type="bp_admin_access"/><BioProject id="PRJNA448797" entrez_id="448797" type="bp_data_submission"/><StudyNameEntrez>CALGB 40601: Randomized Phase 3 Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Breast Cancer </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="whole_targ_exome"/><StudyType22 name="rnaseq_whole_targ_transcriptome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="germline"/><StudyType22 name="dna"/><StudyType22 name="rna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>germline</StudyType><StudyType>dna</StudyType><StudyType>rna</StudyType><StudyType>whole_exome</StudyType><StudyType>whole_transcriptome</StudyType><StudyType>rna_seq_derived_expression</StudyType></StudyTypes><Funding>U10CA031946</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="CAREYL" aid="2" auth="eRA" login="CAREYL" fname="LISA" mname="" lname="CAREY" email="Lisa_Carey@med.unc.edu"><Role allow_direct_access="true">PI</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILL</Organization></Person><Person nedid="0011263528" aid="1" auth="cit" login="mooneym" fname="Margaret" mname="Marian" lname="Mooney" email="mm723k@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="PASPEARS" aid="2" auth="eRA" login="PASPEARS" fname="Patricia" mname="" lname="Spears" email="paspears@med.unc.edu"><Role>PI_ASSIST</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILLDUKE UNIVERSITY</Organization></Person><Person nedid="0012988688" aid="1" auth="cit" login="popovan" fname="Natalia" mname="V" lname="Popova" email="popovan@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>Funding: The Alliance for Clinical Trials in Oncology NIH-NCI grants U10CA180821 and CALGB U10CA031946; Alliance Statistical Center Grant U10CA180882 and CALGB U10CA33601; Alliance NCTN Biorepository and Biospecimen Resource 5U24CA196171.   CALGB 40601 study PI Lisa M. Carey. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. U10CA031946; U10CA180821</acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=28797&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx" md5="36771c6ad50340f0d6ced43a3dd3e2d0" size="57789" modDate="2018-04-03T07:16:35-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=36239&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx.pdf" md5="9ab18a3c50e6a616490b932445e92d12" size="444372" modDate="2019-09-12T09:18:46-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="2831" CGType="cg_class_HMB" title="Health/Medical/Biomedical (COL)" name="HMB-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to NCICTEPDAR@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPDAR@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="27599" whole_study_id="27599" phs="001570" v="1" p="1" createDate="2017-12-14T09:07:11-05:00" completedByGPADate="2018-04-03T07:20:03-05:00" modDate="2020-09-01T09:58:51-05:00" maxParentChildStudyModDate="2020-09-01T09:58:51-05:00" handle="CALGB_40601" num_participants="265"><StudyInfo accession="phs001570.v1.p1" parentAccession="phs001570.v1.p1"><BioProject id="PRJNA448796" entrez_id="448796" type="bp_admin_access"/><BioProject id="PRJNA448797" entrez_id="448797" type="bp_data_submission"/><StudyNameEntrez>CALGB 40601: Randomized Phase 3 Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Breast Cancer </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="whole_targ_exome"/><StudyType22 name="rnaseq_whole_targ_transcriptome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="germline"/><StudyType22 name="dna"/><StudyType22 name="rna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>genotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>germline</StudyType><StudyType>dna</StudyType><StudyType>rna</StudyType><StudyType>whole_exome</StudyType><StudyType>whole_transcriptome</StudyType><StudyType>rna_seq_derived_expression</StudyType></StudyTypes><Funding>U10CA031946</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="CAREYL" aid="2" auth="eRA" login="CAREYL" fname="LISA" mname="" lname="CAREY" email="Lisa_Carey@med.unc.edu"><Role allow_direct_access="true">PI</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILL</Organization></Person><Person nedid="0011263528" aid="1" auth="cit" login="mooneym" fname="Margaret" mname="Marian" lname="Mooney" email="mm723k@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="PASPEARS" aid="2" auth="eRA" login="PASPEARS" fname="Patricia" mname="" lname="Spears" email="paspears@med.unc.edu"><Role>PI_ASSIST</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILLDUKE UNIVERSITY</Organization></Person><Person nedid="0012988688" aid="1" auth="cit" login="popovan" fname="Natalia" mname="V" lname="Popova" email="popovan@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>Funding: The Alliance for Clinical Trials in Oncology NIH-NCI grants U10CA180821 and CALGB U10CA031946; Alliance Statistical Center Grant U10CA180882 and CALGB U10CA33601; Alliance NCTN Biorepository and Biospecimen Resource 5U24CA196171.   CALGB 40601 study PI Lisa M. Carey. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. U10CA031946; U10CA180821</acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=28797&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx" md5="36771c6ad50340f0d6ced43a3dd3e2d0" size="57789" modDate="2018-04-03T07:16:35-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=28805&amp;file=get&amp;page=file" filename="dbGaP NCI DUC-final-v171214 CALGB 40601.docx.pdf" md5="21addf5b4a105cf0aa73ab6617126487" size="632806" modDate="2018-04-03T08:21:41-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="2831" CGType="cg_class_HMB" title="Health/Medical/Biomedical (IRB, COL)" name="HMB-IRB-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="Yes" collaboration-required="Yes"><Use-Restriction>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide documentation of local IRB approval.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to the NCICTEPpubs@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPpubs@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>